Rosetta Genomics Ltd. is a molecular diagnostics company advancing microRNA-based diagnostics discovered and developed through its microRNAs and platform technologies. The Company has developed platform technologies for the identification, extraction, quantification and analysis of microRNAs from a range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects in cancer, cardiovascular diseases and other indications. The Company's four commercial oncology tests have been launched in multiple countries across the world. The Company is working to develop additional tests in the cancer realm and in other fields. It is marketing and selling the four diagnostic tests based on its microRNA technologies, which include Rosetta Cancer Origin Test, Rosetta Lung Cancer Test, Rosetta Kidney Cancer Test and Rosetta Mesothelioma Test. The Company's therapeutic pipeline consists of the projects, such as CMV Therapeutic and Rimonim Consortium.